General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Psoriatic Arthritis
Last updated December 19, 2017
Ravicti (glycerol phenylbutyrate)
Status:
Concluded with an LOI
Manufacturer:
Horizon Therapeutics Ireland DAC
Indication:
Urea cycle disorders
Last updated December 12, 2017
Status:
Concluded with an LOI
Manufacturer:
Actelion Pharmaceuticals Ltd.
Indication:
Pulmonary Arterial Hypertension
Last updated December 12, 2017
Status:
Negotiations were not pursued
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Acute Lymphoblastic Leukemia (ALL)
Last updated December 8, 2017
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Myeloma
Last updated December 8, 2017
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Myeloma
Last updated December 8, 2017
Methadose (methadone hydrochloride)
Status:
Concluded without agreement
Manufacturer:
Mallinckrodt Canada ULC
Indication:
Opioid Dependence
Last updated November 30, 2017
Status:
Concluded without agreement
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Prevention of atherothrombotic events with history of myocardial infarction
Last updated November 30, 2017
Tafinlar/Mekinist (dabrafenib/trametinib)
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Non-Small Cell Lung Cancer (with CNS metastases)
Last updated November 30, 2017
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Severe Eosinophilic Asthma
Last updated November 24, 2017